Free website hits

Good morning, everyone, and how are you today? We are doing just fine, thank you, now that the Pharmalot campus has settled down. Our short person is hunched over a laptop, the official mascot is bounding through snow drifts and, best of all, our plumbing is working again. This calls for a celebratory cup of stimulation — vanilla caramel cream, in fact. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some fresh tidbits. Hope your day goes well, and do stay in touch. …

A study released this week suggested that a vaccine developed by AstraZeneca (AZN) and Oxford University not only protected clinical trial participants from developing disease, but also may significantly reduce transmission of the virus. In the recent burst of data on Covid-19 vaccines, that suggestion stood out. Media reports seized on a reference in the paper that a single dose cut positive test results by 67%. But the paper, which has not yet been peer-reviewed, does not prove or even claim that — although it hints at the possibility, STAT explains.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]